Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Next Previous
Trial Profile

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMpassion130
  • Sponsors Chugai Pharmaceutical; Genentech; Roche

Most Recent Events

  • 09 Nov 2022 Cost effectiveness analysis from KEYNOTE-355 and IMPASSION-130 presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 07 Jun 2022 Results evaluating biological changes in the TME induced by atezolizumab and nPearly on treatment (OT) and at the time of progressive disease (PD) in IMpassion130 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Results of post-hoc comparative analysis assessing Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation from peripheral blood mononuclear cells collected from patients from IMpassion130 and IMpassion131 studies, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top